Moderna and Merck Report Phase 3 Results for Cancer Vaccine

Merck and Moderna reported positive Phase 3 clinical trial results for their personalized cancer vaccine, intismeran autogene, in combination with Keytruda, showing a 42% reduction in the risk of death or tumor recurrence and a 38% reduction in cancer spread among over 1,100 melanoma patients. The companies plan to seek US regulatory approval and aim for a product launch in 2027. Despite meeting primary endpoints, some analysts raised concerns about the technology's applicability to other cancer types and its potential pricing impact on oncology franchises.